End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
9.69
CNY
|
+4.98%
|
|
+11.38%
|
-15.89%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
11,312
|
12,979
|
13,348
|
6,804
|
4,034
|
4,073
|
Enterprise Value (EV)
1 |
10,888
|
12,766
|
13,074
|
6,781
|
4,044
|
4,024
|
P/E ratio
|
42
x
|
33.3
x
|
63.4
x
|
-62.6
x
|
-13.9
x
|
-9.52
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.86
x
|
8.02
x
|
8.67
x
|
4.78
x
|
2.95
x
|
3.54
x
|
EV / Revenue
|
7.56
x
|
7.89
x
|
8.49
x
|
4.77
x
|
2.96
x
|
3.49
x
|
EV / EBITDA
|
26.9
x
|
25
x
|
44.4
x
|
135
x
|
-96.8
x
|
-40.7
x
|
EV / FCF
|
-104
x
|
-73.5
x
|
113
x
|
-32.4
x
|
272
x
|
19.4
x
|
FCF Yield
|
-0.96%
|
-1.36%
|
0.89%
|
-3.09%
|
0.37%
|
5.14%
|
Price to Book
|
5.94
x
|
5.57
x
|
5.59
x
|
2.75
x
|
1.75
x
|
2.18
x
|
Nbr of stocks (in thousands)
|
354,606
|
354,606
|
350,698
|
350,698
|
353,521
|
353,521
|
Reference price
2 |
31.90
|
36.60
|
38.06
|
19.40
|
11.41
|
11.52
|
Announcement Date
|
4/23/19
|
4/14/20
|
4/28/21
|
4/14/22
|
4/7/23
|
4/24/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,440
|
1,618
|
1,540
|
1,422
|
1,368
|
1,151
|
EBITDA
1 |
405
|
511.2
|
294.7
|
50.17
|
-41.78
|
-98.87
|
EBIT
1 |
338.4
|
429.1
|
218.6
|
-46.41
|
-132.4
|
-198.8
|
Operating Margin
|
23.51%
|
26.53%
|
14.19%
|
-3.26%
|
-9.68%
|
-17.27%
|
Earnings before Tax (EBT)
1 |
310.9
|
445.7
|
245.3
|
-120.4
|
-283.3
|
-453.4
|
Net income
1 |
268.1
|
390.6
|
210.7
|
-110.8
|
-254.8
|
-427.2
|
Net margin
|
18.62%
|
24.15%
|
13.68%
|
-7.79%
|
-18.62%
|
-37.1%
|
EPS
2 |
0.7600
|
1.100
|
0.6000
|
-0.3100
|
-0.8200
|
-1.210
|
Free Cash Flow
1 |
-104.3
|
-173.8
|
116
|
-209.4
|
14.89
|
207
|
FCF margin
|
-7.25%
|
-10.74%
|
7.53%
|
-14.73%
|
1.09%
|
17.97%
|
FCF Conversion (EBITDA)
|
-
|
-
|
39.35%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
55.06%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/23/19
|
4/14/20
|
4/28/21
|
4/14/22
|
4/7/23
|
4/24/24
|
Fiscal Period: December |
2022 Q1
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
-11.93
|
Net margin
|
-
|
EPS
2 |
-0.0400
|
Dividend per Share
|
-
|
Announcement Date
|
4/14/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
10.1
|
-
|
Net Cash position
1 |
424
|
212
|
274
|
22.7
|
-
|
48.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.2419
x
|
-
|
Free Cash Flow
1 |
-104
|
-174
|
116
|
-209
|
14.9
|
207
|
ROE (net income / shareholders' equity)
|
14.8%
|
18.1%
|
8.63%
|
-4.44%
|
-10.4%
|
-20.1%
|
ROA (Net income/ Total Assets)
|
10.6%
|
10.2%
|
4.33%
|
-0.86%
|
-2.46%
|
-4.18%
|
Assets
1 |
2,525
|
3,821
|
4,867
|
12,920
|
10,343
|
10,218
|
Book Value Per Share
2 |
5.370
|
6.570
|
6.810
|
7.040
|
6.510
|
5.270
|
Cash Flow per Share
2 |
1.190
|
1.160
|
1.790
|
1.180
|
0.9400
|
0.9600
|
Capex
1 |
166
|
295
|
113
|
337
|
73.3
|
55.1
|
Capex / Sales
|
11.52%
|
18.25%
|
7.31%
|
23.67%
|
5.36%
|
4.79%
|
Announcement Date
|
4/23/19
|
4/14/20
|
4/28/21
|
4/14/22
|
4/7/23
|
4/24/24
|
|
1st Jan change
|
Capi.
|
---|
| -15.89% | 474M | | -17.08% | 8.39B | | +45.61% | 3.74B | | -36.69% | 2.55B | | -8.41% | 2.48B | | -12.96% | 2.32B | | -6.49% | 1.93B | | -17.24% | 1.6B | | -37.21% | 1.28B | | +5.14% | 1.08B |
Medical & Diagnostic Laboratories
|